Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor
ContributorsAhmed, Kamal; Koval, Alexey; Xu, Jiabin![orcid](assets/images/orcid.png)
; Bodmer, Alexandre; Katanaev, Vladimir![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
Published inCancer Letters, vol. 449, p. 45-55
Publication date2019
Abstract
Keywords
- Triple-negative breast cancer
- Clofazimine
- Wnt signaling
- Targeted therapy
- Drug combination
Research group
Funding
- Autre - Swiss cancer league KFS-2978-08-2012
- Autre - Novartis MBR 17C153
Citation (ISO format)
AHMED, Kamal et al. Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor. In: Cancer Letters, 2019, vol. 449, p. 45–55. doi: 10.1016/j.canlet.2019.02.018
Main files (1)
Article (Accepted version)
Identifiers
- PID : unige:115677
- DOI : 10.1016/j.canlet.2019.02.018
- PMID : 30771433
ISSN of the journal0304-3835